During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Opinion|Videos|April 24, 2024
RESPONSE Trial and Hydroxyurea Resistance
Author(s)Andrew Kuykendall, MD
Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.
Advertisement
Case: Management of Advanced Polycythemia Vera in a 67-Year-Old-Male
Clinical Presentation:
- 67-year-old male presented with frequent headache and dizziness
- Prior medical history is notable for smoking.
- PMH: unremarkable, no splenomegaly
Initial Clinical Workup and Diagnosis:
- Labs:
- Hemoglobin, 20.5 g/dL
- White blood cell count, 13 K/L
- Platelet count, 380 K/L
- Hematocrit, 68%
- JAK2-V617F mutation- variant allele frequency of 65%
- Bone marrow biopsy: trilineage proliferation and pleiomorphic megakaryocytes
- The patient started phlebotomy, aspirin, and Hydroxyurea (HU)
Initial Treatments:
- The patient started phlebotomy, aspirin and HU.
- Over the next year the patient underwent several phlebotomies and remained on aspirin and 2000 mg/day of HU
Disease Progression and Subsequent Treatments:
February 2019
- 2 phlebotomies since the last visit 3 months earlier
- He is also experiencing fatigue and night sweats.
- Labs
- Hgb, 15.5 g/dL
- WBC, 13 K/L
- Platelet count, 380 K/L
- Hematocrit, 47%
Advertisement
Related to this article
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5